Patents for A61P 35 - Antineoplastic agents (221,099)
01/2003
01/30/2003CA2417907A1 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
01/30/2003CA2417845A1 Preventive or therapeutic drugs for cancers containing cyanidin compounds as the active ingredient
01/30/2003CA2395992A1 Method for the screening of compounds that inhibit the interaction between a proline-rich peptide and a sh3 domain comprising peptide
01/29/2003WO2002010350A1 Method of proliferating natural killer cells
01/29/2003EP1279739A1 Recombinant vectors derived from adeno-associated virus expressing TAM67 for gene therapy
01/29/2003EP1279677A1 Gd3-mimetic peptides
01/29/2003EP1279676A1 Porphyrin derivatives for photodynamic therapy
01/29/2003EP1279406A1 Transporters and drug delivery system by using the same
01/29/2003EP1279404A1 Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
01/29/2003EP1279039A1 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
01/29/2003EP1278893A2 Diagnosis of diseases associated with dna replication
01/29/2003EP1278874A2 Hybrid protein and vector encoding the same for inhibition of angiogenesis
01/29/2003EP1278869A2 Proteases
01/29/2003EP1278868A2 Novel mutated form of arginine deiminase
01/29/2003EP1278859A2 Human protein kinases and protein kinase-like enzymes
01/29/2003EP1278851A1 Humanised antibodies to the epidermal growth factor receptor
01/29/2003EP1278846A2 Cytoskeleton-associated proteins
01/29/2003EP1278843A2 Rna metabolism proteins
01/29/2003EP1278842A2 Dna encoding the prost 03 polypeptide
01/29/2003EP1278840A2 Isolated human g-protein coupled receptors of the mas proto-oncogene subfamily, nucleic acid molecules encoding human gpcr proteins, and uses thereof
01/29/2003EP1278838A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
01/29/2003EP1278827A2 Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
01/29/2003EP1278826A1 Novel proteins
01/29/2003EP1278825A2 Methods of producing membrane vesicles
01/29/2003EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents
01/29/2003EP1278770A1 Human wingless-like gene
01/29/2003EP1278767A1 Albumin fusion proteins
01/29/2003EP1278766A2 Polynucleotides for diagnosing mammary gland cancer
01/29/2003EP1278763A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
01/29/2003EP1278759A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
01/29/2003EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
01/29/2003EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
01/29/2003EP1278735A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents
01/29/2003EP1278734A2 Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
01/29/2003EP1278732A1 1-aroyl-piperidinyl benzamidines
01/29/2003EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments
01/29/2003EP1278547A2 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
01/29/2003EP1278544A2 Albumin fusion proteins
01/29/2003EP1278542A2 Molecular antigen arrays and vaccines
01/29/2003EP1278539A1 Omp protein associated with autologous and/or heterologous tumour cell lysate
01/29/2003EP1278536A1 Depletion method of blood plasma ascorbate
01/29/2003EP1278535A2 Uses of tgap7 for the modulation of leucocyte activation
01/29/2003EP1278528A1 Nucleoside analogs with carboxamidine-modified bicyclic base
01/29/2003EP1278523A2 Combination of progesterone and mifepristone for cancer therapy
01/29/2003EP1278521A2 Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
01/29/2003EP1278519A2 Method for treating a patient with neoplasia by treatment with a topoisomerase i inhibitor
01/29/2003EP1278518A2 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
01/29/2003EP1278512A2 Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
01/29/2003EP1278412A2 Polymer conjugates of ara-c and ara-c derivatives
01/29/2003EP1064257B1 Anti-tumour agents
01/29/2003EP1064253B1 Anti-tumour agents
01/29/2003EP1033369B1 5H-PYRANO [2,3-d:6,5-d']DIPYRIMIDINE DERIVATIVES HAVING AN ANTIBACTERIAL, ANTIVIRAL AND IMMUNO-MODULATING ACTIVITY
01/29/2003EP1030836B1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
01/29/2003EP1024815B1 Pharmaceutical compositions for oral administration of molecular iodine
01/29/2003EP0858465B1 Anti-tumoral protein
01/29/2003EP0832081B1 Bicyclic-aromatic compounds
01/29/2003CN1394206A Novel vitamin D analogues
01/29/2003CN1394205A Indazole compounds, pharmaceutical compositions, and their use for mediating or inhibiting cell proliferation
01/29/2003CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors
01/29/2003CN1394141A Fulvestrant formulation
01/29/2003CN1394139A Anticancer agents
01/29/2003CN1393559A Configuration and application of liver cancer specific genetically engineered adenovirus
01/29/2003CN1393475A Micromolecular lung cancer antibody targeted immunotoxin and its equipment, preparing process and usage
01/29/2003CN1393451A Platinum match and its preparing process and usage
01/29/2003CN1393438A Taxane derivative and its preparing process and usage
01/29/2003CN1393244A Chinese medicine for treating esophagus cancer and cardia cancer
01/29/2003CN1393236A Medicine 'Aibixiao' for treating cancer
01/29/2003CN1393234A 'Jingema' honeyed cream for antipyresis and detoxication
01/29/2003CN1100063C Ginkgo testa polysaccharide and preparing process of pharmaceutical thereof
01/29/2003CN1100058C Novel intermediates and process for manufacture of camptothecin derivatives (CPT-11) and related compounds
01/29/2003CN1100046C 喹唑啉衍生物 Quinazoline derivatives
01/29/2003CN1100036C Prourokinase and urokinase affinity ligand and its usage
01/29/2003CN1099894C Vaccine composition for eliciting immune response against N-glycolylated gangliosides and its use
01/29/2003CN1099892C Process for separating antineoplastic component from glossy ganoderma spore
01/29/2003CN1099891C Composite glossy ganoderma spore powder
01/29/2003CN1099890C Guangyehehuan anticancer medicine and its prepn. method
01/29/2003CN1099886C Medicine for nasopharyngeal cancer and its preparing process
01/29/2003CN1099869C Photosensibilizers
01/29/2003CA2417579A1 Method of proliferating natural killer cells
01/28/2003WO2002018372A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
01/28/2003US6512123 Antiproliferative agents
01/28/2003US6512104 Interleukin-1β converting enzyme like cysteine protease
01/28/2003US6512102 Compositions and methods of diagnosis and treatment using casein kinase I
01/28/2003US6512101 Branched hydrazone linkers
01/28/2003US6512096 Prostate cell surface antigen-specific antibodies
01/28/2003US6512007 Treatment of inflammatory processes induced by excessive expression of the IL-6-induced acute phase proteins
01/28/2003US6511990 Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
01/28/2003US6511988 Prevention binding of transcription factor tozinc finger binding compounds
01/28/2003US6511986 Method of treating estrogen receptor positive carcinoma
01/28/2003US6511978 Pyrrole derivatives useful for farnesyl transferase inhibitors and their preparations
01/28/2003US6511971 Substituted perhalogenated phthalocyanines
01/28/2003US6511847 Recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect in the transfected cells; tumor suppressor gene
01/28/2003US6511825 Cell signaling polypeptides and nucleic acids
01/28/2003US6511676 Forming cisplatin and ethanol buffered solution; combining with a negatively charged phosphatidyl glycerol lipid deriva-tive; able to reach primary tumors and their metastases after intravenous injection; breast and prostate cancer
01/28/2003US6511670 (poly)thiaalkynoic compounds and pharmaceutical/cosmetic compositions comprised thereof
01/28/2003US6511661 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract
01/28/2003US6511648 Vitronectin receptor antagonist pharmaceuticals
01/28/2003CA2318432C The use of isolated domains of type iv collagen to modify cell and tissue interactions
01/28/2003CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy
01/28/2003CA2123124C Photosensitizers